Penumbra Is Poised For Growth As Blood Clot Awareness Rises: Analyst
Penumbra Is Poised For Growth As Blood Clot Awareness Rises: Analyst
Shares of Penumbra Inc (NYSE:PEN) recovered slightly in early trading on Tuesday, after a week of correction.
Penumbra Inc(纽交所:PEN)的股价在周二早盘略有回升,此前经历了一周的调整。
The Alameda, California-based company is likely to gain market share in the mechanical thrombectomy (MT) segment, according to Oppenheimer.
总部位于加利福尼亚州阿拉米达的公司有可能在机械血栓抽吸(MT)领域获得市场份额,Oppenheimer表示。
MT is a minimally invasive procedure that removes a blood clot from an artery.
MT是一种微创手术,可以清除动脉中的血块。
Analyst Steven Lichtman initiated coverage of Penumbra with an Outperform rating and a price target of $275.
分析师Steven Lichtman对Penumbra的评级为跑赢大盘,目标价格为275美元。
The Penumbra Thesis: The company could generate mid-teens sales growth and over 30% earnings growth, Lichtman said.
Penumbra的投资论点:该公司可能实现中等十几的销售增长和超过30%的盈利增长,Lichtman表示。
Check out other analyst stock ratings.
查看其他分析师的股票评级。
More than 700,000 people in the U.S. currently suffer from deep vein thrombosis (DVT) and pulmonary embolism (PE). Penumbra and its peers run clinical trials "to drive awareness" of MT benefits, Lichtman stated.
美国目前有超过700,000人患有深静脉血栓(DVT)和肺栓塞(PE)。Penumbra及其同行开展临床试验,以"提升MT益处的认知",Lichtman指出。
"We forecast mid-to-high teens US market growth near-term," the analyst wrote. The surgeons surveyed expect MT's share to increase to around 50% in DVT and about 60% in PE over the next few years, he added.
"我们预测短期内美国市场将实现中到高十几的增长,"分析师写道。被调查的外科医生预计,未来几年MT在DVT中的市场份额将增加到约50%,在PE中将达到约60%,他补充道。
International thrombectomy remains an upside opportunity in the near term, Lichtman further said.
国际血栓切除术在短期内仍然是一个上升机会,Lichtman进一步表示。
Price Action: Shares of Penumbra had risen by 0.37% to $248.16 at the time of publication on Tuesday.
价格动态:截至周二发布时,Penumbra的股票上涨了0.37%,达248.16美元。
Read More:
阅读更多:
- Evaluating Globus Medical: Insights From 11 Financial Analysts
- 评估Globus Medical:来自11位分析师的见解
Image: Shutterstock
图片:shutterstock